{"organizations": [], "uuid": "9cc663345458e17e1eee2ba7d88cfd273d570aab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/06/the-associated-press-adverum-biotechnologies-posts-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Adverum Biotechnologies posts 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T02:15:00.000+02:00", "replies_count": 0, "uuid": "9cc663345458e17e1eee2ba7d88cfd273d570aab"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/06/the-associated-press-adverum-biotechnologies-posts-4q-loss.html", "ord_in_thread": 0, "title": "Adverum Biotechnologies posts 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "menlo park", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "menlo park", "sentiment": "none"}], "organizations": [{"name": "adverum biotechnologies inc.", "sentiment": "negative"}, {"name": "adverum biotechnologies", "sentiment": "negative"}, {"name": "advm", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MENLO PARK, Calif. (AP) _ Adverum Biotechnologies Inc. (ADVM) on Tuesday reported a loss of $14.8 million in its fourth quarter.\nOn a per-share basis, the Menlo Park, California-based company said it had a loss of 32 cents.\nThe results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.\nThe gene therapy company posted revenue of $461,000 in the period.\nFor the year, the company reported that its loss narrowed to $56.1 million, or $1.29 per share. Revenue was reported as $1.8 million.\nAdverum Biotechnologies shares have more than doubled since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.20, more than doubling in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on ADVM at https://www.zacks.com/ap/ADVM", "external_links": [], "published": "2018-03-07T02:15:00.000+02:00", "crawled": "2018-03-07T13:50:27.008+02:00", "highlightTitle": ""}